Designing phase 3 sepsis trials: application of learned experiences from critical care trials in acute heart failure

Alexandre Mebazaa1,2,3⁎, Pierre François Laterre4, James A. Russell5, Andreas Bergmann6, Luciano Gattinoni7, Etienne Gayat8, Michael O. Harhay9, Oliver Hartmann6, Frauke Hein6, Anne Louise Kjolbye10, Matthieu Legrand11, Roger J. Lewis12, John C. Marshall13, Gernot Marx14, Peter Rademacher15, Mathias Schroeder6, Paul Sciagalla6, Wendy Gattis Stough16, Joachim Struck6, Greet Van den Berghe17, Mehmet Birhan Yilmaz18 and Derek C. Angus19,20

Abstract
Substantial attention and resources have been directed to improving outcomes of patients with critical illnesses, in particular sepsis, but all recent clinical trials testing various interventions or strategies have failed to detect a robust benefit on mortality. Acute heart failure is also a critical illness, and although the underlying etiologies differ, acute heart failure and sepsis are critical care illnesses that have a high mortality in which clinical trials have been difficult to conduct and have not yielded effective treatments. Both conditions represent a syndrome that is often difficult to define with a wide variation in patient characteristics, presentation, and standard management across institutions. Referring to past experiences and lessons learned in acute heart failure may be informative and help frame research in the area of sepsis. Academic heart failure investigators and industry have worked closely with regulators for many years to transition acute heart failure trials away from relying on dyspnea assessments and all-cause mortality as the primary measures of efficacy, and recent trials have been designed to assess novel clinical composite endpoints assessing organ dysfunction and mortality while still assessing all-cause mortality as a separate measure of safety. Applying the lessons learned in acute heart failure trials to severe sepsis and septic shock trials might be useful to advance the field. Novel endpoints beyond all-cause mortality should be considered for future sepsis trials.

Keywords: Sepsis, Clinical trials as topic, Heart failure, Mortality, Multiple organ failure

Introduction
Sepsis, defined as "life-threatening organ dysfunction due to a dysregulated host response to infection" [1], is a major cause of mortality and morbidity worldwide [2–6]. Literature estimates of sepsis incidence vary widely [7]. One US study reported an absolute incidence ranging from 300 to 1031 cases per 100,000 population [7, 8]. The annual incidence of sepsis globally has been roughly estimated at 15 to 19 million [7, 9]. A systematic review of 33 studies originating in North America, Europe, Asia, and Australia found a population incidence for hospital-treated sepsis of 256 cases per 100,000 person-years [10]. The authors extrapolated these findings to estimate a global incidence for sepsis of 30.7 million cases, contributing to an estimated 6 million deaths each year [10].

Sepsis mortality has declined over the last decade from ~40 to ~20% [11]. Improved processes of care (e.g., earlier diagnosis; timely resuscitation with appropriate therapies; low tidal volume during mechanical ventilation) may explain this observation [12–15]. However, neuromuscular, psychological, metabolic, cardiovascular, and renal complications persist and lead to impaired long-term outcomes among sepsis survivors [16, 17]. In addition, many sepsis patients are elderly and have other life-limiting comorbidities. Survival may be less important to these patients than measures reflecting independence and quality of life [18]. The long-term outcome and morbidity burden of sepsis survivors is an emerging, important research and clinical care concern.

⁎ Correspondence: alexandre.mebazaa@lrb.aphp.fr
1University Paris Diderot, Sorbonne Paris Cité, Paris, France
2U942 Inserm, APHP, Paris, France
3Full list of author information is available at the end of the article

© 2016 Mebazaa et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Effective therapies are needed to better manage sepsis patients [19]. Therapeutic goals include not only improving survival but also reducing morbidity, preventing organ failure, and shortening convalescence [2, 20]. Substantial attention has been directed at reducing mortality in sepsis, but all recent multinational trials have failed to improve survival [21–26].

Other critical care conditions (e.g., acute heart failure) have faced similar challenges with efforts to prolong survival in clinical trials. Acute heart failure and sepsis are both critical care illnesses with high mortality. Both conditions represent syndromes with wide variation in patient characteristics, presentation, and standard management. Further, the underlying pathophysiology in both conditions is related to many processes, but pharmacologic interventions generally target single pathways and have not translated into survival benefits. All-cause mortality is usually the primary endpoint chosen for phase 3 pivotal trials in sepsis and acute heart failure, but no treatments to date have effectively reduced the high mortality associated with either of these conditions (Fig. 1). In a survey of acute heart failure experts, most felt it was unlikely that improvements in short-term mortality could be shown as a single primary endpoint in acute heart failure trials [27]. Thus, recent and ongoing acute heart failure trials have been designed with composite clinical primary endpoints, reserving all-cause mortality assessments for safety [28]. This approach recently adopted in some acute heart failure trials may help frame research in sepsis, since both of these critical care illnesses have faced similar challenges in clinical research.

The European Drug Development Hub brought together experts in critical care/sepsis and acute heart failure with the objective of sharing the collective clinical research experience in these critical care illnesses. The ultimate goal was to discuss better approaches to conducting clinical trials in critical care illnesses with high mortality (i.e., sepsis and acute heart failure) to promote advances in the care of these patients (Paris, France, January 2015). This paper summarizes the key developments from the meeting, focusing on clinical trial designs and endpoints that should be considered for use in future sepsis trials.

**Review**

**Clinical trials in sepsis**

*Why have outcomes failed to improve in clinical trials?*

An overview of the results from a selection of recent large, rigorously designed and conducted sepsis clinical trials reveals a consistent theme (Table 1). All trials were designed with short-term all-cause mortality as the primary endpoint, but none of the interventions has improved short-term survival for a variety of possible reasons (Table 2).

Mortality rates due to sepsis are declining but remain high [5]. Statistical power is dependent on several parameters, including the population’s baseline risk, the modifiable mortality, and on the treatment effect size and its variability within the study sample. In some recent sepsis trials, all-cause mortality ranged from 19 to 45 % depending on the study population and follow-up duration (Table 1). Achieving lower than expected event...
### Table 1: Overview of key recent critical care sepsis trials

| Trial            | Design                          | Intervention                                                                 | Study population                                                                 | Mean SOFA \[ F \] score | Endpoint                                                                 | Length of follow-up | N of deaths     | Primary endpoint results                                                                 |
|-----------------|--------------------------------|------------------------------------------------------------------------------|----------------------------------------------------------------------------------|--------------------------|--------------------------------------------------------------------------|----------------------|----------------|-----------------------------------------------------------------------------------------|
| ALBIOS [22]     | Multicenter, open-label, randomized, controlled | 20% albumin + crystalloid vs. crystalloid alone for 28 days or until ICU discharge | N = 1818≥18 years, clinical criteria for severe sepsis [76]                      | Albumin 8 (6–10) vs. crystalloid 8 (5–10) \[ F \], median (interquartile range) | All-cause mortality | 28 days          | 285 albumin vs. 288 crystalloid 31.8% albumin vs. 32% crystalloid (RR 1.00, 95% CI 0.87–1.14, \( P = 0.94 \)) |
| SEPSISPAM [21]  | Multicenter, open-label, randomized | Vasopressor treatment adjusted to maintain MAP of 80–85 mmHg (high target) vs. 65–70 mmHg (low target) for 5 days or until vasopressor support weaned | N = 776 Septic shock (Table 2) refractory to fluid resuscitation, requiring vasopressors | Low target 10.8 ± 3.1 vs. high target 10.7 ± 3.1 \[ F \] | All-cause mortality | 28 days          | 142 high target vs. 132 low target 36.6% high target vs. 34% low target (HR for high target 1.07, 95% CI 0.84–1.38, \( P = 0.57 \)) |
| ProCESS [26]    | Multicenter, randomized          | Protocol-based EGDT vs. protocol-based standard therapy vs. usual care       | N = 1341 Suspected sepsis with ≥2 criteria for SIRS, [76] and refractory hypotension or serum lactate ≥4 mmol/L | Not reported              | All-cause in-hospital death                                               | 60 days             | 92 EGDT vs. 81 standard therapy vs. 86 usual care 21% EGDT vs. 18.2% standard therapy vs. 18.9% usual care Combined protocol-based groups vs. usual care RR 1.04, 95% CI 0.82–1.31, \( P = 0.83 \) |
| Rosuvastatin for ARDS \[ 25 \] | Multicenter, randomized, placebo-controlled, double-blind | Enteral rosuvastatin vs. placebo                                             | N = 745 Positive pressure mechanical ventilation, \( P_{O_2} \) to \( F_O_2 \) ratio ≤300, bilateral infiltrates on CXR without evidence of left atrial hypertension, known or suspected infection, and ≥1 criteria for SIRS (Table 2) | Not reported              | All-cause mortality before hospital discharge home or until study day 60 | 60 days             | 108 rosuvastatin vs. 91 placebo 28.5% rosuvastatin vs. 24.9% placebo; difference 4.0 (−2.3 to 10.2), \( P = 0.21 \); enrollment stopped prematurely for futility |
| TRISS [23]      | Multicenter, randomized, parallel-group | Leuko-reduced blood transfusion at lower (≤7 g/dL) vs. higher (≥9 g/dL) Hgb thresholds | N = 1000 (Hgb ≥9 g/dL), fulfilleed septic shock criteria (Table 2), Hgb ≥9 g/dL | Both groups 10 (8–12) \[ F \], median (interquartile range) | All-cause mortality | 90 days          | 216 lower Hgb vs. 223 higher Hgb 43% lower threshold vs. 45% higher threshold (RR 0.94, 95% CI 0.78 to 1.09, \( P = 0.44 \)) |
| ARISE [24]      | Multicenter, randomized, parallel-group | EGDT vs. usual care for 6 h                                                  | N = 1600 Suspected or confirmed infection, ≥2 criteria for SIRS (Table 2), refractory hypotension or hypoperfusion, identified in the ED within 6 h of presentation | Not reported              | All-cause mortality                                                       | 90 days             | 147 EGDT vs. 150 usual care 186% EGDT vs. 18.8% usual care (RR 0.98, 95% CI 0.80 to 1.21, \( P = 0.9 \)) |
Table 1 Overview of key recent critical care sepsis trials (Continued)

| PROMISE [31] | Pragmatic, open, multicenter, parallel-group, randomized, controlled trial | 6-h EGDT resuscitation protocol vs. usual care | N = 1,260 Known or presumed infection, \( \geq 2 \) SIRS criteria, and either refractory hypotension or hyperlactatemia within 6 h after ED presentation | EGDT 4.2 ± 2.4 vs. usual care 4.3 ± 2.4d | All-cause mortality 90 days 184 EGDT vs. 181 usual care | 29.5 % EGDT vs. 29.2 % usual care (RR 1.01, 95 % CI 0.85 to 1.20, \( P = 0.9 \)) |

*ICU intensive care unit, MAP mean arterial pressure, EGDT early goal-directed therapy, SIRS systemic inflammatory response syndrome, CXR chest radiography, Hgb hemoglobin, ED emergency department

*aIncludes subscores ranging from 0 to 4 for each of five components (respiratory, coagulation, liver, cardiovascular, and renal components), with higher scores indicating more severe organ dysfunction. The scoring was modified by excluding the assessment of cerebral failure (the Glasgow Coma Scale), which was not performed in these patients, and by decreasing to 65 mmHg the mean arterial pressure threshold for a cardiovascular subscore of 1, for consistency with the hemodynamic targets as defined according to the early goal-directed therapy

*bIncludes subscores ranging from 0 to 4 for each of five components (circulation, lungs, liver, kidneys, and coagulation). Aggregated scores range from 0 to 20, with higher scores indicating more severe organ failure

*cSubscores ranging from 0 to 4 for each of six organ systems (cerebral, circulation, pulmonary, hepatic, renal, and coagulation). The aggregated score ranges from 0 to 24, with higher scores indicating more severe organ failure. One variable was missing for 51 patients in the higher-threshold group and for 64 in the lower-threshold group, so their values were not included

*dScores range from 0 to 24, with higher scores indicating a greater degree of organ failure. The SOFA score was calculated on the basis of the last recorded data before randomization. The SOFA renal score was based on the plasma creatinine level only and did not include urine output

*eARDS acute respiratory distress syndrome

*fSOFA sequential organ failure assessment
rates in trials (e.g., due to declining overall mortality, unintended enrollment of a lower-risk population, intentional exclusion of patients with an imminent risk of death) reduces the likelihood of identifying true treatment effects. As the overall mortality rate declines in the general sepsis population, the potential absolute effect of any given treatment is attenuated, if by nothing else, a lower fraction of modifiable mortality [19, 29]. At the same time, if baseline risk is higher than estimated, more patients will be needed as the expected treatment effect decreases (Fig. 2).

Over- or under-estimating treatment effects should be avoided when designing clinical trials [30]. Researchers have struggled and often over-estimated control group mortality when planning sample size and power estimates. For example, usual care group mortality rates were over-estimated by 5.1% in Protocolized Care for Early Septic Shock (PROCESS) [26], 9.7% in Sepsis and Mean Arterial Pressure (SEPSISPAM) [21], 19.4% in Australasian Resuscitation in Sepsis Evaluation (ARISE) [24], and 10.8% in Protocolized Management in Sepsis (ProMISE) [31], similar to previous over-estimates in septic shock trials (Vasopressin and Septic Shock Trial (VASST) over-estimate was 11%) [32].

Sepsis is a complex syndrome characterized by the interplay of many pathways and systems. Sepsis therapies must either (1) control several pathways with several interventions or (2) hit “upstream” nodes that control a number of pathways. The treatment approach for sepsis has ranged from inhibiting the uncontrolled, inflammatory host response to enhancing the host immune response [33]. These seemingly conflicting approaches illustrate the complexity of the process and the significant (and ongoing) evolution in the understanding of sepsis pathophysiology. Analogously, the failure of positive inotropes to improve outcomes in clinical heart failure trials [34] was initially unexpected, but it was better understood as the knowledge of heart failure pathophysiology evolved.

Whether sepsis treatments targeting a single aspect of this complex syndrome could be reasonably expected to reduce all-cause mortality is uncertain. All-cause mortality is a robust endpoint because it reflects the net benefit of an intervention [28]. A benefit on all-cause mortality shows that the effect of the intervention is strong enough to overcome the influence of events on which the treatment has no or minimal effect [28]. While this approach works well when most deaths are directly related to the disease being studied, it may be less informative when heterogeneity in cause of death is common and mortality is often attributable to factors indirectly related to the disease such as occurs in sepsis [35].

In sepsis trials, significant patient heterogeneity exists in time to presentation and diagnosis, organisms(s), type and source of infection, organ involvement, degree of organ impairment, severity of illness, location of enrollment (e.g., emergency department vs. ICU), pre-existing conditions, and differences in standard of care across institutions or geographical regions (Additional file 1: Table S1) [36]. Recent consensus definitions for sepsis and septic shock should help to reduce this variation in future clinical trials (Additional file 1: Table S1) [1, 37]. The selection of sites participating in a clinical trial can substantially influence endpoints (e.g., variation in comorbidities or application of background therapies can impact event rates across high and low enrolling centers) and make interpretation of
trial results difficult, a challenge that has been experienced in acute heart failure trials [38]. Genetic variants also appear to influence severity [39]. Treatment responses might vary, perhaps considerably, within such a group of patients according to clinical and genetic heterogeneity. Recent observational cohort studies highlighted the wide variation in mortality rates according to infection source [40]. At present, most trials do not consider heterogeneous treatment effects when estimating sample sizes. As a result, subgroup analyses, though often employed, are likely to miss important signals from treatments and interventions [19].

**Approaches to design clinical trials in sepsis**

**Characterization of pathophysiology: matching the treatment to the disease**

Animal models used in sepsis do not accurately reflect the presentation of sepsis in humans [41, 42], in large part because there is no single presentation of sepsis in human disease. Validated and more clinically relevant animal models are needed to understand the disease process and enable therapy selection targeting specific pathophysiologic mechanisms. These models should replicate the duration of clinical intensive care treatment [42], integrate standard intensive care measures and advanced supportive care [42, 43], investigate higher order species to minimize the physiological and immunological differences between small animal species and humans [44–46], and investigate older animals with chronic comorbidities to better reflect real-world patient populations [42]. An alternate approach that might be more informative is to use the heterogeneity of animal models to understand predictors of treatment response, and then seek to replicate the predictors in a human trial. This approach has been explored in a systematic review of anti-tumor necrosis factor (anti-TNF) animal studies [47]. Biomarkers may play a role if they aid in diagnosis, prognosis (e.g., troponin in acute coronary syndrome [48] or N-terminal brain natriuretic peptide (NT-proBNP) in heart failure [49]), or identify patient subsets likely to respond to specific interventions (i.e., predictive biomarkers). Multi-biomarker approaches may be promising [50].

Although many advances in cardiovascular medicine were realized using the concept of large, simple trials, moving towards precision medicine has been proposed [51] (e.g., targeting patients with elevated systolic blood pressure for vasodilator trials in acute heart failure [52]). A similar approach has been suggested for sepsis trials, with emphasis on defining pathophysiology through better pre-clinical models, targeting drug development to specific pathophysiologic abnormalities, and selecting patients with clinical features likely to respond to a specific therapeutic approach or who are at sufficient risk for poor outcomes based on validated risk scores [42].

**Appropriate endpoints for sepsis clinical trials: insights from acute heart failure clinical trials**

**All-cause mortality**

Reducing the morbidity burden in surviving patients is an important therapeutic goal that is not reflected in an all-cause mortality endpoint [53]. All-cause mortality is an appropriate endpoint when the population has a significant mortality risk and minimal competing risks and the intervention has the potential to alter the mortality risk. Short-term survival should predict longer-term survival with an acceptable quality of life. Sepsis satisfies the first criterion, but it performs poorly on the others. First, patients with sepsis die from many causes, but it is often impossible to determine which is primary (e.g., renal, hepatic, pulmonary, cardiac) [33]. Death occurs via many pathways, some of which are unrelated to the therapy being studied and will not be impacted by the treatment (e.g., a decision to withdraw support in many ICU cases [2]). The “noise” of non-response can obscure a beneficial effect on disease-specific death (i.e., the death that the intervention is able to impact). Thus, cause-specific mortality is a more informative endpoint to determine the benefit of a drug or intervention, whereas all-cause mortality is more meaningful when information on the net benefit of an intervention (i.e., benefit in the context of adverse events or non-response) is being sought [54]. In sepsis, cause-specific mortality is difficult to define but perhaps could be achieved in a clinical trial by increasing the “signal” (e.g., enrolling patients with the abnormality targeted by the intervention and exclude patients at low risk of death) and decreasing the “noise” (e.g., excluding patients with competing mortality risks from conditions unrelated to the sepsis episode). Cause-specific mortality might be useful in sepsis trials to identify agents with a significant treatment effect on specific components of the illness.

Similar to sepsis, patients with acute heart failure have high short-term mortality, a factor which usually makes mortality trials easier to conduct. However, in the case of acute heart failure, most therapies primarily target symptoms rather than the underlying pathophysiology that leads to death. Additionally, acute heart failure drugs are administered for a short-duration; both of these factors reduce the likelihood that all-cause mortality will be influenced over the intermediate or long-term (e.g., 180 days). Although the European Medicines Agency guideline still specifies all-cause mortality as the preferred primary endpoint in acute heart failure trials, it states that symptomatic improvement might be acceptable as a primary endpoint for short-term trials provided mortality is not adversely affected [55]. Regulatory agencies have recently agreed to a primary hierarchical clinical composite endpoint in an acute heart failure trial that combines a global assessment of symptoms,
persistent or worsening heart failure requiring an intervention, and all-cause mortality assessed at 6, 24, and 48 h. Patients are categorized as improved (moderate or marked improvement in clinical status at all planned assessments without hospitalization for heart failure or death), unchanged (modest improvement or worsening in clinical status), or worsened (moderate or marked worsening of clinical status at any planned assessment, hospitalization for heart failure requiring intravenous or mechanical interventions, or death). The distribution of patients in each category is compared between treatment groups to assess the treatment effect [56, 57]. This endpoint has the advantage of reflecting considerations that are important to patients (both symptoms and outcomes), and it allows for a short-term assessment of morbidity and mortality during the period when the pharmacologic effect is present. Importantly, long-term all-cause mortality should still be assessed for safety, and the study should be powered to demonstrate that long-term mortality is not increased by a pre-specified safety margin [52].

Regulatory agencies might consider a similar clinical composite endpoint adapted for sepsis trials, where endpoints describing end-organ function, need for mechanical support, or need for other interventions are combined with short-term mortality (ideally sepsis-related mortality if consensus can be reached on a standard definition) as a primary endpoint, with longer-term all-cause mortality assessed for safety. This approach also has the advantage of reflecting relevant factors other than survival that are important to patients. Rigorous definitions for such endpoints are keys to ensure consistency and to reduce bias in the results and to ensure that the endpoint can be translated into a metric that is important to patients.

Non-fatal endpoints

Total or ICU length of stay has been considered as an endpoint for sepsis trials. It is relevant because ICU stays are costly, but it is dependent on external factors that are unrelated to drug therapy (e.g., physician judgment, no accepted standards for discharge readiness, availability of step-down beds, payer influence, local standards of care). These same limitations have been recognized in acute heart failure trials [58]. Thus, the length of stay is unsuitable as a primary endpoint for pivotal trials, but it can be useful as a secondary endpoint or to inform health technology and economic (cost/benefit) assessments. Other problems with using non-fatal endpoints include ascertainment bias, competing risks, and informative dropout when comparing treatment and control groups (i.e., patients who die cannot be hospitalized and patients who die early have decreased length of stay) [19].

Organ dysfunction is a relevant endpoint for sepsis trials. Multiple organs are impaired in sepsis [42], but all-cause mortality is insensitive to determine which organ or organ(s) are the primary driver of death. Conceptually, integrating a measure of organ dysfunction into a mortality endpoint (e.g., days alive and free of organ dysfunction) would provide a more comprehensive assessment of morbidity and mortality. Organ dysfunction is theoretically a more sensitive measure of the effect of an intervention on progression of the sepsis syndrome, but this concept has not yet been validated in trials. Since short-term organ dysfunction is associated with long-term outcome [17, 59], it is plausible that improvements in organ function might translate into improved survival, but this relationship has not yet been shown and the hypothesis still requires confirmation. The primary value of measuring organ dysfunction at the current time is to gain an understanding of how an intervention impacts physiologic and organ function. Correlations between change in short-term organ dysfunction and long-term sepsis-associated morbidity could also be derived from large robust registries that include long-term follow-up and outcomes. If used as an endpoint, organ dysfunction should be pre-defined in the protocol and statistical analysis plan. Ideally, consensus about how to define organ dysfunction should be sought so that definitions are used consistently across clinical trials.

Days alive and free from mechanical ventilation, renal replacement therapy, or vasopressors (i.e., organ failure free days) has also been proposed. These endpoints are clinically meaningful, and widespread use of the Surviving Sepsis Campaign guidelines has led to more consistent timing and application of life support interventions. Nonetheless, the decision to institute supportive therapies is often subjective and can be influenced by external factors (e.g., reimbursement incentives, interactions of various medical specialists (e.g., intensivists and nephrologists)), which introduces increased variability (i.e., random noise) in the study and possibly bias if the study is not blinded. Other complex issues also warrant consideration, including whether patients value more event-free days equally regardless of when they occur (e.g., moving from 0 to 1 day is the same/better/worse than moving from 29 to 30 days), handling inclusion of multiple organs (i.e., are all organs of equal value or should failure in some organs be weighted more heavily than others), and methodology to account for pre-existing organ dysfunction. Interventions can be effective in preventing organ dysfunction (in patients who do not have organ dysfunction) and/or preventing progression of organ dysfunction (in patients who already have some degree of organ dysfunction). An adequate organ dysfunction scoring system must capture both of these possibilities.

Organ dysfunction scoring system must capture both of these possibilities.
In general, there are no accepted surrogates for safety [60], although death is not the only safety measure. Safety is difficult to assess in sepsis trials because of the high incidence of organ dysfunction in sepsis. Differences in organ dysfunction scores between treatment groups could also be seen as a safety outcome (e.g., prevention of organ dysfunction due to side effects of excessive vasopressor doses and duration). Other events (e.g., anaphylaxis) might be relevant for specific drugs. Even if a beneficial effect was shown on organ dysfunction or other non-fatal endpoint, adequate assurance of safety would still have to be demonstrated, either in a pivotal clinical trial, in the entirety of the drug’s database, or based on experience with similar drugs or interventions [60]. Consultation with regulatory agencies is needed to determine the size of the safety database and the confidence level required to rule out an adverse effect on mortality; these decisions are often dependent on the severity of illness in the population studied and the specific benefit of the drug (e.g., a drug that improves a clinically important outcome vs. a drug that improves control of a biomarker).

Role of alternative study designs

Adaptive designs

Adaptive designs or seamless phase II/III designs have the potential to improve the efficiency of clinical trials. Adaptive designs can be particularly useful in fields in which data are limited to inform trial planning assumptions in the areas of expected event rates, anticipated effect sizes, heterogeneity of treatment effect, variance, safety, or drop-outs [61, 62]. In sepsis, many uncertainties exist at the time of trial design, and adaptive design is a promising approach for both exploratory and confirmatory stages of drug development, especially in the context of moving towards exploration of novel endpoints for sepsis trials. These designs are well accepted for feasibility and early phase studies, but as experience with their use has increased, they are becoming more accepted for pivotal trials as well [63]. Potential challenges include maintaining confidentiality and blinding of interim ongoing results and avoiding the introduction of bias resulting from the adaptations [63]. Strict control of type I error risk and understanding the potential biases are important issues; rapid progress is being made around these issues [64, 65].

Realistic trial simulation is the key tool to address these challenges and advance the field. Trial simulation of traditional and adaptive trial designs furthers understanding of strengths and weaknesses of proposed trial designs and will illustrate vulnerabilities from minor deviations to study design assumptions (e.g., event rates, missing data).

Ideally, trial design should be a multi-step, collaborative, and interactive multidisciplinary process between scientific, clinical, and statistical domain experts to increase the quality and chance of success. This concept applies to all types of trials, but it is particularly important for adaptive design. Early interaction with regulators is highly recommended when using adaptive designs in the later stages of a drug development program [61, 62].

Conclusions

Sepsis is a major burden with high mortality, and the lack of progress in identifying effective treatments is discouraging for researchers and industry. The clinical research challenges that have been encountered in sepsis trials closely resemble those experienced by investigators in acute heart failure trials. After decades of research, it has become clear in the acute heart failure community that the substantial patient heterogeneity contributes to the difficulties in identifying effective therapies for the condition. The recent consensus definitions for sepsis and septic shock are important advances in this regard [1, 37].

Table 3 Priorities for future sepsis clinical trials

| Priority |
|------------------|
| 1. Develop more informative studies using animal models |
| 2. Emphasize study of pathophysiology |
| 3. Identify biomarkers, molecular signals, or genetic markers to identify patients having an underlying causal process that might respond to the specific treatment being studied |
| 4. Develop networks of sepsis investigators experienced in clinical trial conduct |
| 5. Apply the recent Third International Consensus Definitions for Sepsis and Septic Shock [1, 37] when determining eligibility criteria |
| 6. Conduct targeted clinical trials in relatively homogeneous groups of patients with characteristics suggestive of treatment response |
| 7. Consider the addition of pre-specified covariate adjustment of the primary endpoint to address the issue of heterogeneity |
| 8. Exclude low-risk patients if appropriate for the intervention being studied |
| 9. Standardize care to reduce variability and random noise but not to the extent that results are not generalizable |
| 10. Develop realistic expectations for treatment effect and power trials accordingly |
| 11. Apply adaptive designs, especially when key variables are uncertain (e.g., event rates, expected treatment effect) |
| 12. Consider targeted primary endpoints with all-cause mortality reserved for safety |
| 13. Develop consensus in the field for standard trial definitions/criteria for interventions if used as endpoints (e.g., vasopressors, mechanical ventilation, renal replacement therapy) |
| 14. Collaborate with regulators to modify approach to clinical trial design in this field |
| 15. Develop robust registries to test external validity of the results of trials in broader patient populations |
| 16. Discovery and development of a diagnostic that predicts a higher chance of response to a specific intervention |
Additionally, assessing all-cause mortality alone is insufficient to fully characterize the burden of disease because it omits important aspects of symptoms and functional status. Academic heart failure investigators and industry have worked closely with regulators for many years to transition acute heart failure trials away from relying on short-term symptoms and all-cause mortality as the primary efficacy measures, and ongoing trials are assessing novel clinical composite endpoints reflecting organ dysfunction and mortality while still evaluating all-cause mortality as a separate safety measure. Applying the lessons learned in acute heart failure trials to sepsis trials might be useful to advance the field (Table 3). Selecting high-risk patients with clinical phenotypes considered likely to respond to the intervention under study may help to reduce patient heterogeneity within clinical trials and enable signals of benefit to be more readily detected. Additionally, novel endpoints beyond all-cause mortality should be considered for future sepsis trials.

Additional file

Additional file 1: Table S1. This table describes the definitions of sepsis and septic shock that have been used in pivotal sepsis trials. (DOCX 21 KB)

Abbreviations

ADHERE: Acute Decompensated Heart Failure National Registry; AHEAD: Acute Heart Failure Database; ALARM: Acute Heart Failure Global Registry of Standard Treatment; ALBIOS: Albumin Italian Outcome Sepsis Study; Anti-TNF: anti-tumor necrosis factor; ARDS: acute respiratory distress syndrome; ARSE: Australasian Resuscitation in Sepsis Evaluation; ATTEND: Acute Decompensated Heart Failure Syndrome; CXR: chest radiography; ED: emergency department; EGDT: early goal-directed therapy; EHF’S II: Second EuroHeart Failure Survey; Hgb: hemoglobin; ICU: intensive care unit; MAP: mean arterial pressure; NT-proBNP: N-terminal pro brain natriuretic peptide; OPTIMIZE: Organized Program to Initiate Lifesaving Treatment in Hospitalized Patients with Heart Failure; PaCO2: partial pressure of arterial carbon dioxide; PROCESS: Protocolized Care for Early Septic Shock; ProMISE: Protocolized Management in Sepsis; SEPSISPAM: Sepsis and Mean Arterial Pressure; SIRS: systemic inflammatory response syndrome; TRISS: Transfusion Requirements in Septic Shock; VASTT: Vasopressin and Septic Shock Trial.

Competing interests

Alexandre Mebazaa received a speaker’s honoraria from The Medicines Company; Novartis, Orion, Roche, and Servier and fees for Advisory Boards and Steering Committees from Cardiorentis, The Medicines Company, Adrenomed, MyCarris, ZS Pharma, and Critical Decisions. James A. Russell patents owned by the University of British Columbia (UBC) that are related to PCSK9 inhibitor(s) and sepsis and related to the use of vasopressin in septic shock. Dr. Russell is an inventor on these patents. Dr. Russell is a founder, Director, and shareholder in Cyon Therapeutics Inc. (developing a sepsis therapy). Dr. Russell has share options in Leading Biosciences Inc. Dr. Russell reports receiving consulting fees from Cubist Pharmaceuticals (formerly Trius Pharmaceuticals) (developing antibiotics), Ferring Pharmaceuticals (manufactures vasopressin and is developing selepressin), Gifols (sells albumin), MedImmune (regarding sepsis), Leading Biosciences (developing a sepsis therapeutic), La Jolla Pharmaceuticals (developing a sepsis therapeutic), CytoViva (developing a sepsis diagnostic), and Sirus Genomics Inc. (now closed; had done pharmacogenomics research in sepsis). Dr. Russell reports having received grant support from Sirus Genomics and Ferring Pharmaceuticals that was provided to and administered by UBC.

Andreas Bergmann is an employee of Adrenomed AG. Research reported in this publication was supported by the National Heart, Lung, and Blood Institute of the National Institutes of Health under Award Number F31HL127947 awarded to Michael O. Harhay. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Oliver Hartmann is an employee of Adrenomed AG. Frauke Hein is a cofounder and employee of Adrenomed AG. Anne Louise Kjølbye is an employee of Ferring Pharmaceuticals. Dr. Lewis serves as the senior medical scientist at Berry Consultants, LLC, a statistical consulting group that specializes in the design and support of adaptive clinical trials, including adaptive clinical trials focused on the evaluation of treatments for severe sepsis and septic shock. John C. Marshall received personal fees (DSMB member) from Asahi Kasei. Gernot Marx received research grants from EU project THALEA, BBraun Melsungen AG, personal fees (honorary for lecturing and consulting) from BBraun Melsungen AG, Adrenomed, Philips and a patent pending for modulation of TLR4-signaling pathway. Peter Rademacher received research grants from Adrenomed AG, Boehringer Ingelheim Pharma GmbH & Co., German Ministry of Defense, and Pixel SA and personal fees from Boehringer Ingelheim Pharma GmbH & Co. Mathias Schroeder is an employee of Adrenomed AG. Wendy Gatts Stough is a consultant to European Drug Development Hub, Relypsa, CHU Nancy, European Society of Cardiology, Heart Failure Association of the European Society of Cardiology, Heart Failure Society of America, Overcome, Stealth BioTherapeutics, Covis Pharmaceuticals, University of Gottingen, and University of North Carolina. Joachim Struck is an employee of Adrenomed AG. Derek C. Angus received personal fees from Bayer HealthCare, Ferring Pharmaceuticals, GlaxoSmithKline, Ibis Biosciences, and MedImmune (consulting, advisory boards).

All other authors declare that they have no competing interests.

Authors’ contributions

AM conceived, planned, and organized the meeting where discussions on this manuscript topic took place. AM and WGS drafted the manuscript. All authors presented and participated in the discussions during the meeting held in Paris France, January 2015. All authors critically revised the manuscript for important intellectual content. All authors have read and approved the final manuscript.

Acknowledgements

The authors thank EDDH - Fondation Transplantation for the logistical and administrative support.

Author details

1. Université Paris Diderot, Sorbonne Paris Cité, Paris, France. 2. U942 Inserm, APHP, Paris, France. 3. APHP, Department of Anesthesia and Critical Care, Hôpitaux Universitaires Saint Louis-Lariboisière, Paris, France. 4. Department of Critical Care Medicine, St. Luke University Hospital, Université Catholique de Louvain (UCL), Brussels, Belgium. 5. Center for Heart Lung Innovation and the Division of Critical Care Medicine, St. Paul’s Hospital, University of British Columbia, Vancouver, Canada. 6. Adrenomed AG, Hennigsdorf, Germany. 7. Università di Milano, Fondazione IRCCS Ca’ Granda, Ospedale Maggiore Policlinico, Milan, Italy. 8. Département d’Anesthésie – Réanimation – SMUR, Hôpitaux Universitaires Saint Louis – Lariboisière, INSERM – UMR 942, Assistance Publique – Hôpitaux de Paris, Université Paris Diderot, Paris, France. 9. Division of Epidemiology, Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 10. Ferring Pharmaceuticals, Copenhagen, Denmark. 11. Department of Anesthesiology, Critical Care and Burn Unit, St. Louis Hospital, Université Paris 7 Denis Diderot, UMR-S942, Inserm, Paris, France. 12. Department of Emergency Medicine, Harbor-UCLA Medical Center, Torrance, CA, USA. 13. Department of Surgery, Interdepartmental Division of Critical Care Medicine, University of Toronto, St. Michael’s Hospital, Toronto, Ontario, Canada. 14. Department of Intensive Care and Intermediate Care, University Hospital RWTH Aachen, Aachen, Germany. 15. Institut für Anästhesiologische Pathophysiologie und Verfahrensentwicklung, Universitätsklinikum, Ulm, Germany. 16. Campbell University College of Pharmacy and Health Sciences, Buies Creek, NC, USA. 17. Clinical Department and Laboratory of Intensive Care Medicine, Division of Cellular and Molecular
References

1. Seymour CW, Lix VV, Iwashyna TJ, Bruninkhorst FM, Rea TD, Scherag A, et al. Assessment of Clinical Criteria for Sepsis: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016; 315:762–74.
2. Kahn JM, Le T, Angus DC, Cox CE, Hough CL, White DB, et al. The epidemiology of chronic critical illness in the United States. Crit Care Med. 2015;43:282–7.
3. Mayr FB, Yende S, Angus DC. Epidemiology of severe sepsis. Virulence. 2014; 5:4–11.
4. Ogura H, Gando S, Saitoh D, Takeya N, Kushimoto S, Fujishima S, et al. Epidemiology of severe sepsis in Japanese intensive care units: a prospective multicenter study. J Crit Therapeut. 2014;20:157–62.
5. Quenot JP, Binquet C, Kara F, Martinet O, Ganster F, Navellou JC, et al. The epidemiology of septic shock in French intensive care units: a prospective multicenter cohort EPIS study. Crit Care. 2013;17:R65.
6. Taniguchi LU, Bierenbach A, Toscano CM, Schettino G, Azevedo L. Sepsis-related deaths in Brazil: an analysis of the national mortality registry from 2002 to 2010. Crit Care. 2014;18:608.
7. Cohen J, Vincent JL, Adhikari NK, Machado FR, Angus DC, Calandra T, et al. Procalcitonin and sepsis: a roadmap for future research. Lancet Infect Dis. 2015;15:581–614.
8. Gaiske DF, Edwards JM, Kallan MJ, Carr BG. Benchmarking the incidence and mortality of severe sepsis in the United States. Crit Care Med. 2013;41:1167–74.
9. Adhikari NK, Fowler RA, Bhagwanjee S, Rubenfeld GD. Critical care and the global burden of critical illness in adults. Lancet. 2010;376:1339–46.
10. Fleischmann C, Scherag A, Adhikari N. Global burden of sepsis: a systematic review (abstract). Crit Care. 2015;19P21.
11. Kaukonen KM, Bailey M, Suzuki S, Pilcher D, Bellomo R. Mortality related to severe sepsis and septic shock among critically ill patients in Australia and New Zealand, 2000-2012. JAMA. 2014;311:1308–16.
12. Eissner MD, Thompson T, Hudson LD, Luce JM, Hayden D, Schoenfeld D, et al. Efficacy of low tidal volume ventilation in patients with different clinical risk factors for acute lung injury and the acute respiratory distress syndrome. Am J Respir Crit Care Med. 2003;168:231–6.
13. Funk DJ, Kumar A. Antimicrobial therapy for life-threatening infections: speed is life. Crit Care Clin. 2011;27:53–76.
14. Gao F, Melody T, Daniels DF, Giles S, Fox S. The impact of compliance with 6-hour and 24-hour sepsis bundles on hospital mortality in patients with severe sepsis: a prospective observational study. Crit Care. 2005;9R764–70.
15. Jones AE, Focht A, Horton JM, Kline JA. Prospective external validation of the clinical effectiveness of an emergency department-based early goal-directed therapy protocol for severe sepsis and septic shock. Chest. 2007; 132:425–42.
16. Linder A, Gud H, Boyd JH, Walley KR, Anis AH, Russell JA. Long-term (10-year) mortality of younger previously healthy patients with severe sepsis/septic shock is worse than that of patients with nonscrotal critical illness and of the general population. Crit Care Med. 2014;42:2211–8.
17. Linder A, Fjell C, Levin A, Walley KR, Russell JA, Boyd JH. Small acute increases in serum creatinine are associated with decreased long-term survival in the critically ill. Am J Respir Crit Care Med. 2014;189:1075–81.
18. Fried TR, Bradley EH, Towle VR, Allore H. Understanding the treatment preferences of seriously ill patients. N Engl J Med. 2002;346:1061–6.
19. Harhay MO, Wagner J, Ratcliffe SJ, Bronheim RS, Gopal A, Green S, et al. Outcomes and statistical power in adult critical care randomized trials. Am J Respir Crit Care Med. 2014;189:1469–78.
20. Dellinger RP, Levy MM, Rhodes A, Annane D, Gerlach H, Opal SM, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock. 2012. Crit Care Med. 2013;41:580–637.
21. Asfar P, Mezzani F, Harnel JF, Greton G, Megarbane B, Anguel N, et al. High versus low blood-pressure target in patients with septic shock. N Engl J Med. 2014;370:1583–93.
22. Caironi P, Tognoni G, Masson S, Fumagalli R, Pesant E, Romero M, et al. Albumin replacement in patients with severe sepsis or septic shock. N Engl J Med. 2014;370:1412–21.
23. Holst LB, Haase N, Wetterle J, Wernerme J, Gatoomsen AB, Karlson S, et al. Lower versus higher hemoglobin threshold for transfusion in septic shock. N Engl J Med. 2014;371:1381–91.
24. Peake SL, Delaney A, Bailey M, Bellomo R, Cameron PA, Cooper DJ, et al. Goal-directed resuscitation for patients with early septic shock. N Engl J Med. 2014;371:1496–506.
25. Truwit JD, Bernard GR, Steingrub J, Matthay MA, Liu KD, Albertson TE, et al. Rosuvastatin for sepsis-associated acute respiratory distress syndrome. N Engl J Med. 2014;370:2191–200.
26. Yealy DM, Kellum JA, Huang DT, Barnato AE, Weissfeld LA, Pike F, et al. A randomized trial of protocol-based care for early septic shock. N Engl J Med. 2014;370:1683–93.
27. Gheorgheida M, Adams KF, Clegand JG, Cotter G, Felker GM, Filipatous GS, et al. Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group. Am J Heart. 2009;159:957–70.
28. Zannad F, Garcia AA, Anker SD, Armstrong PW, Calvo G, Clegand JG, et al. Clinical outcome endpoints in heart failure trials: a European Society of Cardiology Heart Failure Association consensus document. Eur J Heart Fail. 2011;13:1592–3.
29. Yusuf S, Collins R, Petko R. Why do we need some large, simple randomized trials? Stat Med. 1984;3:409–22.
30. Stevenson EK, Rubensen AR, Radin GT, Wiener RS, Walkey AJ. Two decades of mortality trends among patients with severe sepsis: a comparative meta-analysis. Crit Care Med. 2014;42:265–31.
31. Mouncey PR, Osborn TM, Power GS, Harrison DA, Sadique MZ, Greve RD, et al. Trial of early, goal-directed resuscitation for septic shock. N Engl J Med. 2013;372:1301–11.
32. Russell JA, Walley KR, Singer J, Gordon AC, Hebert PC, Cooper DJ, et al. Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med. 2008;358:877–87.
33. Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med. 2003;348:135–50.
34. Cohn JN, Goldstein SO, Greenberg BH, Lorell BH, Bourge RC, Jaski BE, et al. A dose-dependent increase in mortality with vesnarinone among patients with severe heart failure. Vesnarinone Trial Investigators. N Engl J Med. 1998; 339:1810–6.
35. Gayet E, Lemsale L, Payen D. Drotrecogin alfa (activated) in severe sepsis. Lancet Infect Dis. 2013;13:109–10.
36. Gattinoni L, Ranieli VV, Pesenti A. Sepsis: needs for defining severity. Intensive Care Med. 2015;41:551–2.
37. Shankar-Hari M, Phillips GS, Levy ML, Seymour CW, Lix VV, Deutschnah CS, et al. Developing a New Definition and Assessing New Clinical Criteria for Septic Shock: For the Third International Consensus Definitions for Sepsis and Septic Shock (Sepsis-3). JAMA. 2016;315:775–87.
38. Gheorgheida M, Vaduganathan M, Greene SJ, Mentz RJ, Adams JR, Anker SD, et al. Site selection in global clinical trials in patients hospitalized for heart failure: perceived problems and potential solutions. Heart Fail Rev. 2014; 19:135–52.
39. Toubiana J, Courtine E, Pene F, Villon V, Asfar P, Daubin C, et al. IAKI functional genetic variant affects severity of septic shock. Crit Care Med. 2010;38:2287–94.
40. Lelliakovitz A, Dodek PM, Norena M, Wong H, Kumar A, Kumar A. Association between source of infection and hospital mortality in patients who have septic shock. Am J Respir Crit Care Med. 2014;189:1204–13.
41. Opal SM, Dellinger RP, Vincent JL, Masur H, Angus DC. The next generation of sepsis clinical trial designs: what is next after the demise of recombinant human activated protein C?. Crit Care Med. 2014;42:1714–21.
42. Angus DC, van der Poll T. Severe sepsis and septic shock. N Engl J Med. 2013;369:980–51.
43. Fink MP, Heard SO. Laboratory models of sepsis and septic shock. J Surg Res. 1990;49:186–96.
44. Seok J, Warren HS, Cuenca AG, Misdinno MN, Baker HV, Xu W, et al. Genomic responses in mouse models poorly mimic human inflammatory diseases. Proc Natl Acad Sci U S A. 2013;110:3507–12.
45. Osuchowski MF, Remick DG, Lederer JA, Lang CH, Aasen AO, Aibiki M, et al. Abandon the mouse research ship? Not just yet! Shock. 2014;41:463–75.

46. Rademaker P, Haozui P. A mouse is not a rat is not a man: species-specific metabolic responses to sepsis—a nail in the coffin of murine models for critical care research? Intensive Care Med Exp. 2013;1:17.

47. Lorente JA, Marshall JC. Neutralization of tumor necrosis factor in preclinical models of sepsis. Shock. 2005;24 Suppl 1:107–19.

48. Amsterdam EA, Wenger NK, Brindis RG, Casey Jr JE, Ganiats TG, Holmes Jr DR, et al. 2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2014;64:e1–298.

49. Maisel AS, Krishnaswamy P, Nowak RM, McCord J, Hollander JE, Duc P, et al. Rapid measurement of B-type natriuretic peptide in the emergency department: a prospective diagnostic study. N Engl J Med. 2002;347:167–72.

50. Wong HR, Walley KR, Pettia V, Meyer NJ, Russell JA, Karlsson S, et al. Comparing the prognostic performance of ASSIST to interleukin-6 and procalcitonin in patients with severe sepsis or septic shock. Biomarkers. 2012;17:132–5.

51. Jackson N, Attar D, Borentain M, Breithardt G, van Eickels M, Endres M, et al. Improving clinical trials for cardiovascular diseases: a position paper from the Cardiovascular Roundtable of the European Society of Cardiology. Eur Heart J. 2015. doi: 10.1093/eurheartj/ehv213.

52. Mebazaa A, Longoits D, Metra M, Mueller C, Richards AM, Roessig L, et al. Agents with vasodilator properties in acute heart failure: how to design successful trials. Eur J Heart Fail. 2015;17:652–64.

53. Iwashyna TJ, Angus DC. Declining case fatality rates for severe sepsis: good data bring good news with ambiguous implications. JAMA. 2014; 311:1295–7.

54. Zannad F, Stough WG, Pitt B, Cleland JG, Adams KF, Geller NL, et al. Comparison of age and selected first-listed diagnosis: United States, 2007. http://www.cdc.gov/nchs/data/nhds/5hospital/2007hos5_number.pdf.

55. European Medicines Agency (9-20-2012) Guideline on clinical investigation of medicinal products for the treatment of acute heart failure (CHMP/EWP/2986/03 Rev. 1). http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/10/WC500133497.pdf. Accessed 5/1/2015.

56. Mebazaa A, Longrois D, Metra M, Mueller C, Richards AM, Roessig L, et al. Agents with vasodilator properties in acute heart failure: how to design successful trials. Eur J Heart Fail. 2015;17:652–64.

57. Temple R. Are surrogate markers adequate to assess cardiovascular disease patients? JAMA. 1999;282:790–9.

58. Allen LA, Hernandez AF, O'Connor CM, Felker GM. End points for clinical trials in acute heart failure syndromes. J Am Coll Cardiol. 2009;53:2248–58.

59. Nieminen MS, Brutsaert D, Dickstein K, Drexler H, Follath F, Harjola VP, et al. EuroHeart Failure Survey II (EHS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J. 2006;27:727–36.

60. Spinar J, Parenica J, Vitovec J, Widimsky P, Linhart A, Fedorco M, et al. Baseline characteristics and hospital mortality in the Acute Heart Failure Global Survey of Standard Treatment (ALARM-HF). Intensive Care Med. 2011;37:619–26.

61. Sato N, Kajimoto K, Keida T, Mizuno M, Minami Y, Yumino D, et al. Clinical features and outcome in hospitalized heart failure patients: description of population. Eur Heart J. 2006;27:727–36.

62. Bone RC, Balk RA, Cerra FB, Dellinger RP, Fein AM, Knaus WA, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. The ACCP/SCCM Consensus Conference Committee. American College of Chest Physicians/Society of Critical Care Medicine. Chest. 1992;101:1644–55.